# Soligenix

Source: https://onco.cc/companies/soligenix/  
OnCo record `soligenix` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Soligenix is a New Jersey company developing HyBryte, a synthetic hypericin ointment activated by visible light, for early-stage cutaneous T-cell lymphoma, tested in the phase 3 FLASH trials.

## Summary

Soligenix, based in Princeton and listed on Nasdaq, develops treatments for rare diseases and biodefence. Its lead cancer programme is HyBryte (synthetic hypericin), a photosensitiser applied to skin lesions and activated with visible rather than ultraviolet light, for early-stage mycosis fungoides, the commonest form of cutaneous T-cell lymphoma; the FLASH phase 3 trial met its primary endpoint in 2020 and a confirmatory trial, FLASH2, followed at the FDA's request. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: Soligenix, Inc.
- Tags: ctgov-sponsor
- HQ: Princeton, NJ
- Type: biotech
- Website: https://www.soligenix.com

## Sources

- Official website: https://www.soligenix.com
- ClinicalTrials.gov: trials led by Soligenix: https://clinicaltrials.gov/search?lead=Soligenix
- Wikipedia: https://en.wikipedia.org/wiki/Soligenix

## Connected records

- fronts: [Radiation Therapy](https://onco.cc/fronts/radiation/), [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- terms: [Clinical trial](https://onco.cc/terms/clinical-trial/), [Pivotal (registrational) trial](https://onco.cc/terms/pivotal-trial/)
- trials: [Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL](https://onco.cc/trials/nct06470451/), [FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)](https://onco.cc/trials/nct02448381/), [HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL](https://onco.cc/trials/nct06149247/)
- drugs: [Synthetic hypericin](https://onco.cc/drugs/hypericin-sgx301/)
- cancers: [Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)](https://onco.cc/cancers/cutaneous-t-cell-lymphoma/)

---
JSON: https://onco.cc/api/v1/entities/soligenix.json